Sarah Danson
@sdanson1.bsky.social
Professor of Medical Oncology (melanoma and early phase), Ex vivo Clinical Lead & School Director of Research, Sheffield, UK
Great to see @greg-wells.bsky.social and @ljtl.bsky.social on behalf of the Sheffield ex vivo group. Well done!
September 25, 2025 at 10:03 AM
Great to see @greg-wells.bsky.social and @ljtl.bsky.social on behalf of the Sheffield ex vivo group. Well done!
Reposted by Sarah Danson
September 16, 2025 at 7:01 AM
Reposted by Sarah Danson
PREPRINT CLAIMING LINK BETWEEN mRNA VACCINES A D CANCER HAS BEEN WITHDRAWN. Thanks @elisabethbik.bsky.social for your vigilance.
Preprint claiming link between COVID-19 mRNA vaccines and 'transcriptomic dysregulation'/cancer (based on just 10 people who got cancer in the year after vaccination) has been withdrawn.
HT: @reeserichardson.bsky.social
preprints.org/manuscript/2...
See: scienceintegritydigest.com/2025/07/25/p...
HT: @reeserichardson.bsky.social
preprints.org/manuscript/2...
See: scienceintegritydigest.com/2025/07/25/p...
September 12, 2025 at 6:29 AM
PREPRINT CLAIMING LINK BETWEEN mRNA VACCINES A D CANCER HAS BEEN WITHDRAWN. Thanks @elisabethbik.bsky.social for your vigilance.
We are open to recruitment in Sheffield
The DETECTION-2 trial is using targeted blood tests to check for relapse following surgery for patients with resected stage 2B/2C/3A melanoma of the skin.
The trial is recruiting at 12 hospitals across the UK. Watch this video to learn more👉 buff.ly/2yi71QV
#melanoma
The trial is recruiting at 12 hospitals across the UK. Watch this video to learn more👉 buff.ly/2yi71QV
#melanoma
July 31, 2025 at 4:22 PM
We are open to recruitment in Sheffield
Reposted by Sarah Danson
The National Student Survey results are in and we're proud to say that we're top of the Russell Group for the third year in a row! And our Student's Union has been ranked number 1 once again.
A testament to the hard work of our brilliant University community 👏🎉
sheffield.ac.uk/news/sheffie...
A testament to the hard work of our brilliant University community 👏🎉
sheffield.ac.uk/news/sheffie...
July 9, 2025 at 12:08 PM
The National Student Survey results are in and we're proud to say that we're top of the Russell Group for the third year in a row! And our Student's Union has been ranked number 1 once again.
A testament to the hard work of our brilliant University community 👏🎉
sheffield.ac.uk/news/sheffie...
A testament to the hard work of our brilliant University community 👏🎉
sheffield.ac.uk/news/sheffie...
Reposted by Sarah Danson
Proportion of NHS doctors who carry out research has fallen by a quarter over 13 years despite evidence suggesting hospitals with active research programmes deliver better patient outcomes, finds @policyatkings.bsky.social www.timeshighereducation.com/news/nhs-inn... via @helenpacker.bsky.social
NHS innovation ‘at risk’ as university partnerships deprioritised
Report highlights fragmentation of academic links with health system as research drops off NHS agenda
www.timeshighereducation.com
June 20, 2025 at 11:21 AM
Proportion of NHS doctors who carry out research has fallen by a quarter over 13 years despite evidence suggesting hospitals with active research programmes deliver better patient outcomes, finds @policyatkings.bsky.social www.timeshighereducation.com/news/nhs-inn... via @helenpacker.bsky.social
Reposted by Sarah Danson
Impressive poster from Dr Sophie Williams @sheffielduni.bsky.social on the microenvironment in GBM. Also her Supervisor @sdanson1.bsky.social #SMPHResearch&Innovation
June 19, 2025 at 8:02 AM
Impressive poster from Dr Sophie Williams @sheffielduni.bsky.social on the microenvironment in GBM. Also her Supervisor @sdanson1.bsky.social #SMPHResearch&Innovation
This is superb news. Something to really celebrate. Thanks to all involved
The QS World University Rankings 2026 have just been released and we’ve placed 92nd within the World Top 100! Huge congratulations and thanks to everyone in the University of Sheffield community for this achievement; from staff and students to alumni, supporters and friends around the world!
June 19, 2025 at 7:27 AM
This is superb news. Something to really celebrate. Thanks to all involved
Great work from Sophie Williams on brain ageing in the glioblastoma tumour microenvironment
Well done @callumblee.bsky.social @ljtl.bsky.social and Jamie.
June 19, 2025 at 6:36 AM
Great work from Sophie Williams on brain ageing in the glioblastoma tumour microenvironment
Sheffield Ex Vivo Group out in force at Sheffield #smph_research&innovation meeting today. Callum Blee, Louis Lane and Jamie Adams pictured. Great to see
June 18, 2025 at 8:53 PM
Sheffield Ex Vivo Group out in force at Sheffield #smph_research&innovation meeting today. Callum Blee, Louis Lane and Jamie Adams pictured. Great to see
Reposted by Sarah Danson
We are delighted to announce, along with Cancer Research UK (@cancerresearchuk.org), The University of Manchester (@manchester.ac.uk) and The Christie NHS Foundation Trust, the appointment of Professor Samra Turajlić as our new Director! ⭐
Full story here: www.cruk.manchester.ac.uk/news/profess...
Full story here: www.cruk.manchester.ac.uk/news/profess...
June 18, 2025 at 9:21 AM
We are delighted to announce, along with Cancer Research UK (@cancerresearchuk.org), The University of Manchester (@manchester.ac.uk) and The Christie NHS Foundation Trust, the appointment of Professor Samra Turajlić as our new Director! ⭐
Full story here: www.cruk.manchester.ac.uk/news/profess...
Full story here: www.cruk.manchester.ac.uk/news/profess...
Enjoyed today. Looking forward to hearing more tomorrow
We're at @sheffielduni.bsky.social's School of Medicine & Population Health #Research & #Innovation Meeting today.
Prof Christine Le Maitre kicked off the day with the welcome. Great to see so many from across the school gathered together to connect and share research.
#SMPH_Research&Innovation
Prof Christine Le Maitre kicked off the day with the welcome. Great to see so many from across the school gathered together to connect and share research.
#SMPH_Research&Innovation
June 18, 2025 at 4:52 PM
Enjoyed today. Looking forward to hearing more tomorrow
Christine Le Maitre opening our annual meeting #SMPH_Research&Innovation. Apologies I cannot rotate!!
June 18, 2025 at 8:40 AM
Christine Le Maitre opening our annual meeting #SMPH_Research&Innovation. Apologies I cannot rotate!!
Reposted by Sarah Danson
Exciting opportunity to join the cancer research community in Sheffield!!
📣 Postdoctoral position available!!!
Are you interested in translating molecular cell biology into potential cancer therapy?
This project will explore the role of EGFR trafficking in chemotherapy resistance in #breastcancer
🔬 Prof Liz Smythe lab
📅 Deadline: 3rd Jule
👇 www.jobs.ac.uk/job/DNJ622/r...
Are you interested in translating molecular cell biology into potential cancer therapy?
This project will explore the role of EGFR trafficking in chemotherapy resistance in #breastcancer
🔬 Prof Liz Smythe lab
📅 Deadline: 3rd Jule
👇 www.jobs.ac.uk/job/DNJ622/r...
Research Associate (Cell Biology) at University of Sheffield
An opportunity for an academic position as a Research Associate (Cell Biology) is available, as advertised on jobs.ac.uk. Apply now and explore other academic job openings.
www.jobs.ac.uk
June 12, 2025 at 9:30 AM
Exciting opportunity to join the cancer research community in Sheffield!!
Huge congratulations, Jim
We are proud to share that Professor James Catto, Professor of Urological Surgery at @sheffielduni.bsky.social and Honorary Consultant Urological Surgeon at @sth.nhs.uk, has been elected to the prestigious Fellowship of the @cademy of Medical Sciences. 👏
www.sheffield.ac.uk/smph/news/pr...
www.sheffield.ac.uk/smph/news/pr...
Professor James Catto Elected Fellow of the Academy of Medical Sciences
Professor James Catto receives prestigious fellowship, recognised for his outstanding contributions to medical research and patient care.
www.sheffield.ac.uk
June 6, 2025 at 6:51 PM
Huge congratulations, Jim
Reposted by Sarah Danson
Yesterday, Professor Sarah Danson presented the results of the UK DANTE trial at the 2025 American Society of Clinical Oncology (ASCO) annual medical meeting.
Read more: buff.ly/arneMoo
#melanoma #melanomacancer #ASCO25
Read more: buff.ly/arneMoo
#melanoma #melanomacancer #ASCO25
June 4, 2025 at 4:02 PM
Yesterday, Professor Sarah Danson presented the results of the UK DANTE trial at the 2025 American Society of Clinical Oncology (ASCO) annual medical meeting.
Read more: buff.ly/arneMoo
#melanoma #melanomacancer #ASCO25
Read more: buff.ly/arneMoo
#melanoma #melanomacancer #ASCO25
Honoured to present the DANTE trial at ASCO today on behalf of the extended DANTE team. Thank you to all the patients who were involved
June 3, 2025 at 9:50 PM
Honoured to present the DANTE trial at ASCO today on behalf of the extended DANTE team. Thank you to all the patients who were involved
Sophie Trotter at #ASCO25 presenting frailty measures from the STAR renal cell cancer trial @fohsheffield.bsky.social @sheffieldteachinghospitals @universityofleeds.bsky.social
June 2, 2025 at 3:50 PM
Sophie Trotter at #ASCO25 presenting frailty measures from the STAR renal cell cancer trial @fohsheffield.bsky.social @sheffieldteachinghospitals @universityofleeds.bsky.social
Reposted by Sarah Danson
Data from randomized Ph 3 trial that studied time of day of immunotherapy infusion said that infusion before 3:00 PM is far superior to > 3:00 PM. Study by Yongchang Zhang & team. Circadian rhythms with potential major impact on T cell circulation & exhaustion. h/t @stephenvliu.bsky.social #ASCO25
June 2, 2025 at 3:00 PM
Data from randomized Ph 3 trial that studied time of day of immunotherapy infusion said that infusion before 3:00 PM is far superior to > 3:00 PM. Study by Yongchang Zhang & team. Circadian rhythms with potential major impact on T cell circulation & exhaustion. h/t @stephenvliu.bsky.social #ASCO25
Reposted by Sarah Danson
Phase II ipi nivo rela with IL6 inhibitor sarilumab with ORR 68% - highest reported with IO - and grade 3/4 irAEs 12% - lowest reported with combination IO
Jan Mehnert @nyulangone.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
Jan Mehnert @nyulangone.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
June 2, 2025 at 3:06 PM
Phase II ipi nivo rela with IL6 inhibitor sarilumab with ORR 68% - highest reported with IO - and grade 3/4 irAEs 12% - lowest reported with combination IO
Jan Mehnert @nyulangone.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
Jan Mehnert @nyulangone.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
Reposted by Sarah Danson
Melanoma rapid #3 ➡️ High fiber diet of 30-50g daily is tolerable, pCR 57% in neoadj group, grade 3+ irAE 28.8%
Took 400 patients screened to enroll 45 🤔
Yiufan Qiu @mdanderson.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
Took 400 patients screened to enroll 45 🤔
Yiufan Qiu @mdanderson.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
June 2, 2025 at 3:24 PM
Melanoma rapid #3 ➡️ High fiber diet of 30-50g daily is tolerable, pCR 57% in neoadj group, grade 3+ irAE 28.8%
Took 400 patients screened to enroll 45 🤔
Yiufan Qiu @mdanderson.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
Took 400 patients screened to enroll 45 🤔
Yiufan Qiu @mdanderson.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
Reposted by Sarah Danson
Metastatic mucosal melanoma today:
-combination immunotherapy shows lackluster efficacy
-MEKi with 25% ORR
-KIT + anti PD1 with 54.8% ORR
-triplet ICI with 33% ORR
-lenv pembro with 50% ORR
-TIL with 50% ORR
Jun Guo
#ASCO25 #raremelanoma #rarecancers @ascocancer.bsky.social
-combination immunotherapy shows lackluster efficacy
-MEKi with 25% ORR
-KIT + anti PD1 with 54.8% ORR
-triplet ICI with 33% ORR
-lenv pembro with 50% ORR
-TIL with 50% ORR
Jun Guo
#ASCO25 #raremelanoma #rarecancers @ascocancer.bsky.social
June 2, 2025 at 2:07 PM
Metastatic mucosal melanoma today:
-combination immunotherapy shows lackluster efficacy
-MEKi with 25% ORR
-KIT + anti PD1 with 54.8% ORR
-triplet ICI with 33% ORR
-lenv pembro with 50% ORR
-TIL with 50% ORR
Jun Guo
#ASCO25 #raremelanoma #rarecancers @ascocancer.bsky.social
-combination immunotherapy shows lackluster efficacy
-MEKi with 25% ORR
-KIT + anti PD1 with 54.8% ORR
-triplet ICI with 33% ORR
-lenv pembro with 50% ORR
-TIL with 50% ORR
Jun Guo
#ASCO25 #raremelanoma #rarecancers @ascocancer.bsky.social
This is fascinating. When paired with the Manchester abstract @beckilee.bsky.social and colleagues presented, do we need to change practice now?
Winship radiation oncologist Zachary Buchwald, MD, PhD, provides a brief description of a fascinating clinical trial evaluating how time-of-day–specified immunotherapy for patients with advanced melanoma affects their outcome. #ASCO25
June 2, 2025 at 9:04 AM
This is fascinating. When paired with the Manchester abstract @beckilee.bsky.social and colleagues presented, do we need to change practice now?